Author:
Argotti Urimara,Leyens Lada,Lisbona Carlos,López Pilar,Alonso-Orgaz Sergio,Nevado Angel,Cozzi Virginia
Abstract
Abstract
Introduction
Promptly providing new drugs to fulfill unmet medical needs requires changes in drug development and registration processes. Health Authorities (HAs) considered as reference due to their experience and acknowledgement (Food and Drug Administration [FDA] among others) already consider innovative clinical trial (CT) designs and flexible approval procedures, but Latin America (LATAM) regulations are still far. A comparison was performed to identify gaps.
Materials and Methods
CT requirements for drug Marketing Authorization Application (MAA) and CT approval regulations were compared between LATAM and reference HAs (FDA/European Medicines Agency [EMA]/Health-Canada/Swissmedic/Therapeutic Goods Administration [TGA]/Pharmaceuticals and Medical Devices Agency [PMDA]), as of August 2022. Procedure included reference HAs regulations review, item selection, identification in LATAM regulations, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines (ICH-E6[R2]/ICH-E8[R1]) implementation revision.
Results
For MAA, specific application requirements or ICH guideline M4(R4) on common technical document (CTD) adoption are generally stated, and phase-I/III performance is mandatory (explicitly/implicitly). Faster patient access procedures are infrequent: Priority-drug programs, conditional authorizations, or expedited procedures are scarce or non-existent. Regulatory reliance procedures are adopted through different pathways. Regarding CT approval, innovative/complex CT designs are not prohibited but usually omitted. Some countries implemented adapted CT conducting during the COVID-19 pandemic. Early scientific advice meetings (HA-sponsor) are occasionally considered. Most countries are not formally ICH-joined.
Conclusions
LATAM regulations must adapt to new regulatory standards (FDA/EMA/ICH) through implementation of frequent updates, reliance/expedited procedures, early HA-sponsor interactions, innovative/complex CTs, mandatory phase-III reaching elimination, and decentralized elements for CT conducting.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference37 articles.
1. Almufleh A, Joseph J. The time is now: role of pragmatic clinical trials in guiding response to global pandemics. Trials. 2021;22(1):229.
2. Harvin JA, Zarzaur BL, Nirula R, et al. Alternative clinical trial designs. Trauma Surg Acute Care Open. 2020;5(1):e000420.
3. Sharma A, Harrington RA, McClellan MB, et al. Using digital health technology to better generate evidence and deliver evidence-based care. J Am Coll Cardiol. 2018;71(23):2680–90.
4. Spreafico A, Hansen AR, Abdul Razak AR, et al. The future of clinical trial design in oncology. Cancer Discov. 2021;11(4):822–37.
5. European Federation of Pharmaceutical Industries and Associations. EFPIA Clinical Research Expert Group. Innovation in clinical trial design: a review of the clinical trial design landscape. 2020. https://www.efpia.eu/media/547507/efpia-position-paper-innovation-in-clinical-trial-design-white-paper.pdf
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献